Literature DB >> 16849550

Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.

Hong Guo1, Hui Miao, Lizabeth Gerber, Jarnail Singh, Mitchell F Denning, Anita C Gilliam, Bingcheng Wang.   

Abstract

EphA2 receptor tyrosine kinase is frequently overexpressed in different human cancers, suggesting that it may promote tumor development and progression. However, evidence also exists that EphA2 may possess antitumorigenic properties, raising a critical question on the role of EphA2 kinase in tumorigenesis in vivo. We report here that deletion of EphA2 in mouse led to markedly enhanced susceptibility to 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) two-stage skin carcinogenesis. EphA2-null mice developed skin tumors with an increased frequency and shortened latency. Moreover, tumors in homozygous knockout mice grew faster and were twice as likely to show invasive malignant progression. Haploinsufficiency of EphA2 caused an intermediate phenotype in tumor development but had little effects on invasive progression. EphA2 and ephrin-A1 exhibited compartmentalized expression pattern in mouse skin that localized EphA2/ephrin-A1 interactions to the basal layer of epidermis, which was disrupted in tumors. Loss of EphA2 increased tumor cell proliferation, whereas apoptosis was not affected. In vitro, treatment of primary keratinocytes from wild-type mice with ephrin-A1 suppressed cell proliferation and inhibited extracellular signal-regulated kinase 1/2 (ERK1/2) activities. Both effects were abolished in EphA2-null keratinocytes, suggesting that loss of ERK inhibition by EphA2 may be one of the contributing mechanisms for increased tumor susceptibility. Interestingly, despite its tumor suppressive function, EphA2 was overexpressed in skin tumors compared with surrounding normal skin in wild-type mice, similar to the observations in human cancers. EphA2 overexpression may represent a compensatory feedback mechanism during tumorigenesis. Together, these results show that EphA2 is a novel tumor suppressor gene in mammalian skin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849550     DOI: 10.1158/0008-5472.CAN-06-0004

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  74 in total

1.  Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners.

Authors:  Bingcheng Wang
Journal:  Sci Signal       Date:  2011-05-31       Impact factor: 8.192

2.  Specific and shared targets of ephrin A signaling in epidermal keratinocytes.

Authors:  Rebecca Walsh; Miroslav Blumenberg
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

Review 3.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

4.  Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.

Authors:  Weibo Cai; Alireza Ebrahimnejad; Kai Chen; Qizhen Cao; Zi-Bo Li; David A Tice; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-03       Impact factor: 9.236

Review 5.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

6.  Complementary expression and repulsive signaling suggest that EphB2 and ephrin-B1 are possibly involved in epithelial boundary formation at the squamocolumnar junction in the rodent stomach.

Authors:  Kazushige Ogawa; Noritaka Saeki; Yasutaka Igura; Yuta Hayashi
Journal:  Histochem Cell Biol       Date:  2013-07-24       Impact factor: 4.304

7.  Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.

Authors:  Shao-Qing Kuang; Hao Bai; Zhi-Hong Fang; Gonzalo Lopez; Hui Yang; Weigang Tong; Zack Z Wang; Guillermo Garcia-Manero
Journal:  Blood       Date:  2010-01-08       Impact factor: 22.113

8.  Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.

Authors:  Juha P Himanen; Yehuda Goldgur; Hui Miao; Eugene Myshkin; Hong Guo; Matthias Buck; My Nguyen; Kanagalaghatta R Rajashankar; Bingcheng Wang; Dimitar B Nikolov
Journal:  EMBO Rep       Date:  2009-06-12       Impact factor: 8.807

9.  Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice.

Authors:  Tatsuma Okazaki; Amy Ni; Peter Baluk; Oluwasheyi A Ayeni; Jennifer Kearley; Anthony J Coyle; Alison Humbles; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

10.  Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.

Authors:  Helenia Ansuini; Annalisa Meola; Zeynep Gunes; Valentina Paradisi; Monica Pezzanera; Stefano Acali; Claudia Santini; Alessandra Luzzago; Federica Mori; Domenico Lazzaro; Gennaro Ciliberto; Alfredo Nicosia; Nicola La Monica; Alessandra Vitelli
Journal:  J Oncol       Date:  2010-01-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.